BTAI
Price
$1.84
Change
+$0.31 (+20.26%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
11.14M
SBHMY
Price
$9.48
Change
+$0.69 (+7.85%)
Updated
Apr 21 closing price
Capitalization
10.38B
Interact to see
Advertisement

BTAI vs SBHMY

Header iconBTAI vs SBHMY Comparison
Open Charts BTAI vs SBHMYBanner chart's image
BioXcel Therapeutics
Price$1.84
Change+$0.31 (+20.26%)
Volume$13.12K
Capitalization11.14M
Sino Biopharmaceutical
Price$9.48
Change+$0.69 (+7.85%)
Volume$185
Capitalization10.38B
BTAI vs SBHMY Comparison Chart
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. SBHMY commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Buy and SBHMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (BTAI: $1.53 vs. SBHMY: $9.48)
Brand notoriety: BTAI and SBHMY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 71% vs. SBHMY: 78%
Market capitalization -- BTAI: $11.14M vs. SBHMY: $10.38B
BTAI [@Biotechnology] is valued at $11.14M. SBHMY’s [@Biotechnology] market capitalization is $10.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileSBHMY’s FA Score has 2 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • SBHMY’s FA Score: 2 green, 3 red.
According to our system of comparison, SBHMY is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 5 TA indicator(s) are bullish.

  • BTAI’s TA Score: 5 bullish, 3 bearish.

Price Growth

BTAI (@Biotechnology) experienced а +24.39% price change this week, while SBHMY (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

BTAI is expected to report earnings on May 12, 2025.

SBHMY is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SBHMY($10.4B) has a higher market cap than BTAI($11.1M). SBHMY YTD gains are higher at: 13.737 vs. BTAI (-74.425). SBHMY has higher annual earnings (EBITDA): 6.98B vs. BTAI (-56.15M). SBHMY has higher revenues than BTAI: SBHMY (26.2B) vs BTAI (2.28M).
BTAISBHMYBTAI / SBHMY
Capitalization11.1M10.4B0%
EBITDA-56.15M6.98B-1%
Gain YTD-74.42513.737-542%
P/E RatioN/A32.56-
Revenue2.28M26.2B0%
Total Cash233MN/A-
Total Debt105MN/A-
FUNDAMENTALS RATINGS
BTAI vs SBHMY: Fundamental Ratings
BTAI
SBHMY
OUTLOOK RATING
1..100
2944
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9545
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBHMY's Valuation (2) in the null industry is significantly better than the same rating for BTAI (81) in the Biotechnology industry. This means that SBHMY’s stock grew significantly faster than BTAI’s over the last 12 months.

SBHMY's Profit vs Risk Rating (100) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that SBHMY’s stock grew similarly to BTAI’s over the last 12 months.

SBHMY's SMR Rating (98) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that SBHMY’s stock grew similarly to BTAI’s over the last 12 months.

SBHMY's Price Growth Rating (45) in the null industry is somewhat better than the same rating for BTAI (95) in the Biotechnology industry. This means that SBHMY’s stock grew somewhat faster than BTAI’s over the last 12 months.

SBHMY's P/E Growth Rating (21) in the null industry is significantly better than the same rating for BTAI (100) in the Biotechnology industry. This means that SBHMY’s stock grew significantly faster than BTAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAI
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AROC25.650.48
+1.91%
Archrock
STHO7.220.08
+1.19%
Star Holdings
ILAG0.40N/A
+0.73%
Intelligent Living Application Group
DPZ459.54-6.37
-1.37%
Dominos Pizza Inc
EMBC9.99-0.41
-3.94%
Embecta Corp

SBHMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SBHMY has been loosely correlated with TENX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SBHMY jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBHMY
1D Price
Change %
SBHMY100%
N/A
TENX - SBHMY
42%
Loosely correlated
+0.34%
SYBX - SBHMY
34%
Loosely correlated
-0.81%
BTAI - SBHMY
32%
Poorly correlated
N/A
CLRPF - SBHMY
24%
Poorly correlated
+3.67%
VIVS - SBHMY
20%
Poorly correlated
+0.27%
More